Loading...
•
Dec 31, 2020
Cerus Q4 2020 Earnings Report
Cerus Corporation announced record Q4 and full year financial results.
Key Takeaways
Cerus Corporation reported record total fourth quarter revenues of $33.6 million. Product revenue during the fourth quarter of 2020 was $28.2 million, compared to $20.9 million during the same period in 2019. Government contract revenue primarily from the BARDA agreement was $5.4 million during the fourth quarter of 2020, compared to $5.6 million during the same period in 2019. Net loss for the fourth quarter of 2020 was $14.4 million, compared to a net loss of $16.9 million for the fourth quarter of 2019.
Record total fourth quarter and full year 2020 revenues of $33.6 million and $114.2 million, respectively.
Provided 2021 annual product revenue guidance of $106 million to $110 million, representing an approximately 15% to 20% increase over 2020 reported product revenue.
Received FDA approval for the INTERCEPT Blood System for Cryoprecipitation.
Ended 2020 with cash, cash equivalents, and short-term investments of $133.6 million at December 31, 2020.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The Company expects 2021 product revenue to be in the range of $106 million to $110 million. The guidance range represents approximately 15% to 20% growth compared to 2020 reported product revenue.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...